Placebo + Epoetin alfa + Placebo + Epoetin alfa
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Myelodysplastic Syndromes
Conditions
Myelodysplastic Syndromes, Anemia
Trial Timeline
Jun 1, 2008 → Jan 1, 2010
NCT ID
NCT00695396About Placebo + Epoetin alfa + Placebo + Epoetin alfa
Placebo + Epoetin alfa + Placebo + Epoetin alfa is a phase 3 stage product being developed by Johnson & Johnson for Myelodysplastic Syndromes. The current trial status is terminated. This product is registered under clinical trial identifier NCT00695396. Target conditions include Myelodysplastic Syndromes, Anemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00695396 | Phase 3 | Terminated |
Competing Products
20 competing products in Myelodysplastic Syndromes
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| NEX-18a injection + Azacitidine Injection | Nanexa AB | Phase 1 | 28 |
| JSP191 | Jasper Therapeutics | Phase 1 | 25 |
| Humanized anti-CD117 Monoclonal Antibody (JSP191) | Jasper Therapeutics | Phase 1 | 25 |
| GTB-3550 TriKE® Phase I + GTB-3550 TriKE® Phase II | GT Biopharma | Phase 1/2 | 33 |
| Erlotinib Hydrochloride | Astellas Pharma | Phase 2 | 52 |
| Decitabine + Decitabine + Decitabine | Eisai | Phase 2 | 52 |
| Decitabine + Valproic Acid | Eisai | Phase 2 | 52 |
| decitabine + decitabine | Eisai | Phase 2 | 52 |
| decitabine + azacitidine | Eisai | Approved | 85 |
| Decitabine | Eisai | Phase 2 | 52 |
| decitabine + decitabine + decitabine + decitabine | Eisai | Phase 1 | 33 |
| Decitabine, Arsenic Trioxide and Ascorbic Acid | Eisai | Phase 2 | 52 |
| Subcutaneous Decitabine | Eisai | Phase 1 | 33 |
| Decitabine | Eisai | Phase 2 | 52 |
| Galunisertib + Placebo | Eli Lilly | Phase 2/3 | 65 |
| DSP-7888 | Sumitomo Pharma | Phase 1/2 | 41 |
| TP-0184 | Sumitomo Pharma | Phase 1/2 | 41 |
| Decitabine | Johnson & Johnson | Phase 2 | 52 |
| Epoetin alfa | Johnson & Johnson | Phase 2 | 52 |
| ZARNESTRA, tipifarnib, R115777 | Johnson & Johnson | Phase 2 | 52 |